In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

Enhancing care of patients with HR+/HER2- early breast cancer at high risk of recurrence through an expansive curriculum: Real world outcomes (RWO) from a 6 month analysis.

Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit patients ...

Triple-negative breast cancer is particularly aggressive and difficult to treat; but recent research may offer a new way to target the often-deadly disease. A team of researchers from the University ...

A new study has found that a commonly prescribed anti-nausea medication is associated with a better prognosis for women with early-stage breast cancer, particularly triple-negative breast cancer. The ...

March 4, 2011 — Two of the largest studies to date looking at triple-negative breast cancer have found that reproductive factors — specifically, pregnancy and multiple childbirth — and obesity and ...